SCHEMBL6474464

SCHEMBL6474464

O=C(O)Cc1ccc(Oc2cc(I)c(O)cc2I)c(I)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.51
THRA P10827 5/20 0.51
THRB P10828 5/20 0.51
PPARG P37231 4/20 0.51
POLB P06746 3/20 0.51
HIF1A Q16665 3/20 0.51
LMNA P02545 2/20 0.51
HPGD P15428 2/20 0.51
HSD17B10 Q99714 2/20 0.51
RXRA P19793 2/20 0.51
PCNA P12004 2/20 0.51
ABCB11 O95342 1/20 0.51
CYP1A2 P05177 1/20 0.51
PGR P06401 1/20 0.51
CHRM2 P08172 1/20 0.51
HTR1A P08908 1/20 0.51
ADRA2A P08913 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
AR P10275 1/20 0.51
CYP2C9 P11712 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28641777 0.89 GAA (0.53) GAATHRATHRBPPARGPOLB
SCHEMBL6473141 0.86 FFAR1 (0.58) THRATHRBPPARGPOLBHIF1A
SCHEMBL1525944 0.84 THRB (0.63) GAATHRATHRBPPARGPOLB
SCHEMBL1599014 0.83 THRB (0.71) GAATHRATHRBPPARGPOLB
SCHEMBL6474460 0.79 PPARG (0.67) GAATHRATHRBPPARGPOLB
SCHEMBL17141553 0.79 TAAR5 (0.63) GAATHRATHRBPPARGPOLB
SCHEMBL30716576 0.79 HPGD (0.68) GAATHRATHRBPPARGPOLB
SCHEMBL8510463 0.79 HPGD (0.68) GAATHRATHRBPPARGPOLB
SCHEMBL2723833 0.76 GAA (0.68) GAATHRATHRBPPARGPOLB
SCHEMBL16114045 0.76 HPGD (0.68) GAATHRATHRBPPARGPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005123099-A2 METHODS AND COMPOSITIONS FOR ACCELERATING ALCOHOL METABOLISM ENZYMEDIX, INC. (US) 2005-12-29 WO claimed
US-20050271739-A1 Methods and compositions for accelerating alcohol metabolism ENZYMEDIX 2005-12-08 US claimed
EP-0093653-B1 PROCESS FOR THE PREPARATION OF IODO-THYRONINES AND IODO-THYROACETIC ACIDS BY ELECTROCHEMICAL REDUCTION AT A CONTROLLED POTENTIAL SPIRAL Société à responsabilité limitée dite : (FR) 1985-07-10 EP claimed
US-4490221-A Process for preparing iodothyronines and iodothyroacetic acids by electrochemical reduction at controlled potential SPIRAL SOCIETE A RESPONSABILITE LIMITEE DITE (FR) 1984-12-25 US claimed
US-20200224168-A1 COMPOSITIONS AND METHODS FOR ENHANCING MATURATION STATES OF HEALTHY AND DISEASED CARDIOMYOCYTES UNIVERSITY OF WASHINGTON (US) 2020-07-16 US disclosed
CN-111246863-A Compositions and methods for enhancing the maturation state of healthy and diseased cardiomyocytes 华盛顿大学 2020-06-05 CN disclosed
WO-2005123099-A2 METHODS AND COMPOSITIONS FOR ACCELERATING ALCOHOL METABOLISM ENZYMEDIX, INC. (US) 2005-12-29 WO disclosed
US-20050271739-A1 Methods and compositions for accelerating alcohol metabolism ENZYMEDIX 2005-12-08 US disclosed
US-6806359-B1 HAVING BINDING AND/OR TRANSCRIPTION-ACTIVATING CHARACTERISTICS OF A GLUCOCORTICOID/MINERALCORTICOID/THYROID STIMULATING HORMONE RECEPTOR PROTEINS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2004-10-19 US disclosed
US-6794160-B1 COMPRISES PROTEINS HAVING HORMONE-BINDING AND/OR TRANSCRIPTION-ACTIVATING CHARACTERISTICS OF A GLUCOCORTICOID RECEPTOR; PLASMIDS SALK INST FOR BIOLOGICAL STUDI (US) 2004-09-21 US disclosed
US-5606021-A RECOMBINANT PROTEIN WHICH HAS HORMONE BINDING AND TRANSCRIPTION ACTIVATING PROPERTIES CHARACTERISTIC OF MINERALOCORTICOID RECEPTOR THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1997-02-25 US disclosed
US-5597705-A GENETIC ENGINEERING THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1997-01-28 US disclosed
EP-0733705-A1 Hormone receptor compositions and methods THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1996-09-25 EP disclosed
US-5534418-A TRANSCRIPTION IS ACTIVATED BY LIGAND COMPLEXED TO HORMONE RECEPTOR; GENETIC ENGINEERING THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1996-07-09 US disclosed
US-5312732-A DNA and genetic engineering THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1994-05-17 US disclosed
US-5298429-A Monitoring transcription of reporter gene THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1994-03-29 US disclosed
US-5071773-A HORMONE RECEPTOR-RELATED BIOASSAYS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1991-12-10 US disclosed
EP-0287653-A4 HORMONE RECEPTOR COMPOSITIONS AND METHODS. SALK INST FOR BIOLOGICAL STUDI (US) 1989-06-13 EP disclosed
EP-0287653-A1 HORMONE RECEPTOR COMPOSITIONS AND METHODS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1988-10-26 EP disclosed
WO-1988003168-A1 HORMONE RECEPTOR COMPOSITIONS AND METHODS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1988-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050271739-A1 Methods and compositions for accelerating alcohol metabolism ADH1A, ADH1C, ADH5 GAA 1065/4885THRA 2112/4885THRB 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.